Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study.

•Macimorelin is approved for the diagnosis of adult growth hormone deficiency•In this study, single oral doses of macimorelin 0.5–2.0 mg/kg were well tolerated•Macimorelin exposure was less than dose-proportional over this dose range•Growth hormone levels increased after macimorelin dosing•Results support the use of the indicated dose of 0.5 mg/kg